Hedera Dx is dedicated to transforming oncology by providing cutting-edge liquid biopsy solutions that improve patient experiences, outcomes, and journeys, as well as healthcare professional experiences. The company facilitates the prescription, discovery, and development of the next breakthrough precision oncology therapies.

Hedera Dx aims to provide the next billion people with access to modern cancer care through clinic-ready, NGS-based liquid biopsies that enable non-invasive diagnosis, timely treatment selection, and longitudinal disease monitoring. The company adopts a customer- and patient-centric approach, integrating Patient-Reported Outcomes (PROs) and Patient-Reported Experience Measures (PREMs) to deliver products and services that meet the needs of patients and healthcare providers globally.

The company's liquid biopsy solutions allow cancer patients to access non-invasive blood-based diagnostic tests that facilitate better and timely treatment option selection, ultimately improving patient quality of life. Hedera Dx also offers compelling patient support tools and programs, including patient apps, to help understand, treat, and monitor cancer.

The company was founded in 2021 and is led by a team of experienced professionals including Tommi Lehtonen (CEO, Co-founder), Damien Lapray (CCO, Co-founder, PhD), and Christian Meisel (CMO, Co-founder, MD, PhD). The leadership team brings extensive expertise in genetics, oncology, and commercial operations.

Hedera Dx is headquartered at Route de la Corniche 5, 1066 Epalinges, Switzerland. The contact phone number is +41 21 588 16 54.